Send us a text We trace how sex and gender shape drug development, from male-heavy mouse studies to the split results in Lecanemab’s Alzheimer’s trial. Experts explain why regulators should keep approvals moving while demanding smarter design, better reporting, and post-approval answers. For more science stories, visit our website swisinfo.ch, and you can help other people to find our podcast by leaving us a five-star review. Journalist: Jessica Davis Plüss Host: Jo Fahy Audio editor/vide...
All content for The Swiss Connection is the property of SWI swissinfo.ch and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Send us a text We trace how sex and gender shape drug development, from male-heavy mouse studies to the split results in Lecanemab’s Alzheimer’s trial. Experts explain why regulators should keep approvals moving while demanding smarter design, better reporting, and post-approval answers. For more science stories, visit our website swisinfo.ch, and you can help other people to find our podcast by leaving us a five-star review. Journalist: Jessica Davis Plüss Host: Jo Fahy Audio editor/vide...
Turning concrete into a carbon sink: an innovative Swiss approach to decarbonizing the construction industry
The Swiss Connection
14 minutes
11 months ago
Turning concrete into a carbon sink: an innovative Swiss approach to decarbonizing the construction industry
Send us a text This episode explores a groundbreaking Swiss innovation that could revolutionise the construction industry. Join us as we delve into Neustark's pioneering method of turning concrete waste into a carbon sink, permanently removing CO2 from the atmosphere. Discover how this technology not only helps decarbonise the concrete industry but also increases the strength of concrete. We'll discuss the science behind the mineralisation process, the impact of Neustark's 22 operational plan...
The Swiss Connection
Send us a text We trace how sex and gender shape drug development, from male-heavy mouse studies to the split results in Lecanemab’s Alzheimer’s trial. Experts explain why regulators should keep approvals moving while demanding smarter design, better reporting, and post-approval answers. For more science stories, visit our website swisinfo.ch, and you can help other people to find our podcast by leaving us a five-star review. Journalist: Jessica Davis Plüss Host: Jo Fahy Audio editor/vide...
